Skip to main content

Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda®) monotherapy

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari L, Martinetti A, Platania M, Verzoni E, Formisano B, Bajetta R (2007) Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 59:637–642

    PubMed  Article  CAS  Google Scholar 

  2. Yalcin S, Oyan B, Bayraktar Y (2007) Current medical treatment of pancreatic neuroendocrine tumors. Hepatogastroenterology 54:278–284 (Review)

    PubMed  Google Scholar 

  3. Yao J, Hoff P, Phan T, Hess K (2005) Improved progression free survival (PFS) and rapid sustained decreased perfusion among patients with advanced carcinoid treated with bevacizumab. J Clin Oncol Supp 23(16S):4007 (Abstract)

    Google Scholar 

  4. Strosberg JR, Kvols LK (2007) A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opin Investig Drugs 16:219–224 (Review)

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Gregor Fürstenberger.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Fürstenberger, G., Schmid, P., Duquesne, A. et al. Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda®) monotherapy. Cancer Chemother Pharmacol 61, 347–348 (2008). https://doi.org/10.1007/s00280-007-0590-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-007-0590-9

Keywords

  • Bevacizumab
  • Oxaliplatin
  • Capecitabine
  • Octreotide
  • Neuroendocrine Tumor